NCT06135155已完成1 期
A Single-center, Randomized, Double-blind, Parallel Design Phase Ⅰ Study to Compare the Pharmacokinetics of Two Different PEG-rhGH Preparations by Single Administration in Chinese Healthy Adult Male Subjects
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Pharmacokinetics (Peak Plasma Concentration (Cmax) ) of PEG-rhGH with present and new preparation
研究概览
简要总结
The purpose of this study is to compare the pharmacokinetics of the two different PEG-rhGH preparations after a single administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male aged ≥18 years old and≤45 years old;
- •The Body mass index (BMI): 19-26 kg/m2 (inclusive), and body weight ≥50 kg;
- •Normal results of physical examination, vital signs, laboratory tests, 12 lead-ECG, chest X-ray, abdominal ultrasound, or non-clinical significance changes in the assessments above.
排除标准
- •Subjects with a history of hypersensitivity reactions or clinically significant hypersensitivity reactions to drugs containing;
- •Subjects with a clear history of disorders of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, metabolic system, etc., or other diseases deemed unsuitable for participation in the trials by the investigators;
- •Subjects with severe infection, severe trauma, or major surgery prior to screening;
- •Subjects who have received blood transfusions, had blood donors, or lost blood before screening;
- •Subjects who have positive results of human immunodeficiency virus antibodies (HIV-Ab), or hepatitis B surface antigen (HBsAg), or hepatitis C virus antibodies (HCV-Ab), or syphilis specific antibodies (TPPA);
- •Subjects who have participated in clinical trials for medication or medical device prior to screening;etc.
研究组 & 干预措施
PEG-rhGH with new preparation
Experimental
干预措施: PEG-rhGH with new preparation (Drug)
PEG-rhGH with present preparation
Experimental
干预措施: PEG-rhGH with present preparation (Drug)
结局指标
主要结局
Pharmacokinetics (Peak Plasma Concentration (Cmax) ) of PEG-rhGH with present and new preparation
时间窗: 0 hours -168 hours
Pharmacokinetics (Area under the concentration-time curve from time zero to time infinity (AUC0-∞)) of PEG-rhGH with present and new preparation
时间窗: 0 hours -168 hours
Pharmacokinetics (Area under the concentration-time curve from time zero to time t (AUC0-t )) of PEG-rhGH with present and new preparation
时间窗: 0 hours -168 hours
次要结局
- Safety and tolerability (Number of Participants with Abnormal Vital Signs That Are Related to Treatment)(0 hours -168 hours)
- Pharmacokinetics (Half-life (t1/2)) of PEG-rhGH with present and new preparation.(0 hours -168 hours)
- Safety and tolerability（Number of participants with treatment-related adverse events）(0 hours -168 hours)
- Safety and tolerability (Number of Participants with Abnormal Laboratory Values That Are Related to Treatment)(0 hours -168 hours)
- Pharmacokinetics (The time to reach the peak drug concentration (Tmax)) of PEG-rhGH with present and new preparation.(0 hours -168 hours)
- Safety and tolerability (Number of Participants with Abnormal 12-lead ECG QTc Interval That Are Related to Treatment)(0 hours -168 hours)
- Pharmacokinetics (Terminal elimination rate constant (λz)) of PEG-rhGH with present and new preparation.(0 hours -168 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Clinical Trail to Compare Pharmacokinetics of Two PEG-rhGH Injections With Different PreparationsPediatric Growth Hormone Deficiency (PGHD)NCT06135168Changchun GeneScience Pharmaceutical Co., Ltd.60
已完成
1 期
A Bioavailability Study of Two Different PEG-rhGH Preparations.Pediatric Growth Hormone Deficiency (PGHD)NCT06385145Changchun GeneScience Pharmaceutical Co., Ltd.16
已完成
1 期
A Bioequivalence Study of Two Different PEG-rhGH Preparations.Pediatric Growth Hormone Deficiency (PGHD)NCT06331026Changchun GeneScience Pharmaceutical Co., Ltd.87
已完成
2 期
Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)Growth Hormone DeficiencyNCT01090778Aarhus University Hospital8
已完成
3 期
Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone DeficiencyChildhood-onset Growth Hormone DeficiencyPituitary DwarfismNCT00109733EMD Serono31